Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 13/20 | 0.58 |
| ▸ | BCL2 | P10415 | 12/20 | 0.58 |
| ▸ | BCL2L2 | Q92843 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MYD88 | Q99836 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27831693 | 0.87 | BCL2 (0.57) | BCL2L1BCL2BCL2L2LMNAMEN1 | |
| SCHEMBL1677579 | 0.85 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL1677774 | 0.83 | BCL2 (0.63) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL1677857 | 0.82 | BCL2 (0.61) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL1111924 | 0.82 | BCL2 (0.56) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL1111773 | 0.82 | BCL2 (0.59) | BCL2L1BCL2BCL2L2LMNAHTT | |
| SCHEMBL1112389 | 0.82 | BCL2L1 (0.64) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL1677855 | 0.82 | BCL2 (0.56) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL1112004 | 0.82 | BCL2 (0.66) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL27831714 | 0.81 | BCL2 (0.57) | BCL2L1BCL2BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102105449-A | Arylsulfonamide compounds, compositions and methods of use | GENENTECH INC | 2011-06-22 | — | — | CN | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | BCL2L1 13/4885BCL2 3/4885BCL2L2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.